Status: Recruiting
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).
Participants needed: 67
Trial details
Phase: Phase 1Age: 18+Biological sex: MaleType: InterventionalSponsor: Acerand Therapeutics (Hong Kong) LimitedUpdated: Apr 9, 2026Locations: 8
Eligibility criteria
Provide written informed consent [+5]
Receiving any anti-cancer drugs or other treatment, major surgery, extensive rad... [+13]